Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6

Experimental Cell Research

Volumn 315, Issue 11, 2009, Pages 1904-1913

  Dezorella, Nili ^a   Pevsner Fischer, Meirav ^c   Deutsch, Varda ^a   Kay, Sigi ^a   Baron, Shoshana ^a   Stern, Ruth ^a   Tavor, Sigal ^a   Nagler, Arnon ^b,d   Naparstek, Elizabeth ^a,b   Zipori, Dov ^c   Katz, Ben Zion ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Adhesion; Differentiation; Microenvironment; Multiple myeloma; Stroma

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; SYNDECAN 1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCING CELL; MALE; MESENCHYME; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; STROMA CELL;

EID: 67349092202     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.03.016     Document Type: Article

References (42)

1. Orkin S.H., and Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132 (2008) 631-644
2. Wood A.H., Zhang X., Farber D.L., and Strome S.E. CD8+ memory T lymphocytes from bone marrow-immune function and therapeutic potential. Crit. Rev. Immunol. 27 (2007) 527-537
3. Poggi A., and Zocchi M.R. Antigen presenting cells and stromal cells trigger human natural killer lymphocytes to autoreactivity: evidence for the involvement of natural cytotoxicity receptors (NCR) and NKG2D. Clin. Dev. Immunol. 13 (2006) 325-336
4. Wakkach A., Mansour A., Dacquin R., Coste E., Jurdic P., Carle G.F., and Blin-Wakkach C. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 112 (2008) 5074-5083
5. Fairfax K.A., Kallies A., Nutt S.L., and Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin. Immunol. 20 (2008) 49-58
6. Welner R.S., Pelayo R., and Kincade P.W. Evolving views on the genealogy of B cells. Nat. Rev. Immunol. 8 (2008) 95-106
7. Klein U., and Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8 (2008) 22-33
8. Vande Broek I., Vanderkerken K., Van Camp B., and Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin. Exp. Metastasis. 25 (2008) 325-334
9. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., and Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42 (2006) 1564-1573
10. Mitsiades C.S., McMillin D.W., Klippel S., Hideshima T., Chauhan D., Richardson P.G., Munshi N.C., and Anderson K.C. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol. Oncol. Clin. North Am. 21 (2007) 1007-1034 vii-viii
11. Moser K., Tokoyoda K., Radbruch A., MacLennan I., and Manz R.A. Stromal niches, plasma cell differentiation and survival. Curr. Opin. Immunol. 18 (2006) 265-270
12. Shoham T., Sternberg D., Brosh N., Krupsky M., Barda-Saad M., and Zipori D. The promotion of plasmacytoma tumor growth by mesenchymal stroma is antagonized by basic fibroblast growth factor induced activin A. Leukemia 15 (2001) 1102-1110
13. Podar K., Richardson P.G., Hideshima T., Chauhan D., and Anderson K.C. The malignant clone and the bone-marrow environment. Best Pract. Res. Clin. Haematol. 20 (2007) 597-612
14. Chen X.D., Dusevich V., Feng J.Q., Manolagas S.C., and Jilka R.L. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J. Bone Miner. Res. 22 (2007) 1943-1956
15. Balduino A., Hurtado S.P., Frazao P., Takiya C.M., Alves L.M., Nasciutti L.E., El-Cheikh M.C., and Borojevic R. Bone marrow subendosteal microenvironment harbours functionally distinct haemosupportive stromal cell populations. Cell Tissue Res. 319 (2005) 255-266
16. Bianco P., Riminucci M., Gronthos S., and Robey P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19 (2001) 180-192
17. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin. Cancer Res. 11 (2005) 7599-7606
18. Zlei M., Egert S., Wider D., Ihorst G., Wasch R., and Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp. Hematol. 35 (2007) 1550-1561
19. Minges Wols H.A., Underhill G.H., Kansas G.S., and Witte P.L. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 169 (2002) 4213-4221
20. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., Dalva K., Fuhler G., Gratama J., Hose D., Kovarova L., Lioznov M., Mateo G., Morilla R., Mylin A.K., Omede P., Pellat-Deceunynck C., Perez Andres M., Petrucci M., Ruggeri M., Rymkiewicz G., Schmitz A., Schreder M., Seynaeve C., Spacek M., de Tute R.M., Van Valckenborgh E., Weston-Bell N., Owen R.G., San Miguel J.F., Sonneveld P., and Johnsen H.E. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93 (2008) 431-438
21. Nadav L., Katz B.Z., Baron S., Cohen N., Naparstek E., and Geiger B. The generation and regulation of functional diversity of malignant plasma cells. Cancer Res. 66 (2006) 8608-8616
22. Tavor S., Eisenbach M., Jacob-Hirsch J., Golan T., Petit I., Benzion K., Kay S., Baron S., Amariglio N., Deutsch V., Naparstek E., and Rechavi G. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22 (2008) 2151-5158
23. Bommert K., Bargou R.C., and Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer 42 (2006) 1574-1580
24. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97 (2003) 2440-2452
25. Aggarwal R., Ghobrial I.M., and Roodman G.D. Chemokines in multiple myeloma. Exp. Hematol. 34 (2006) 1289-1295
26. de Gorter D.J., Reijmers R.M., Beuling E.A., Naber H.P., Kuil A., Kersten M.J., Pals S.T., and Spaargaren M. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 111 (2008) 3364-3372
27. Meads M.B., Hazlehurst L.A., and Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14 (2008) 2519-2526
28. Dispenzieri A., Zhang L., Katzmann J.A., Snyder M., Blood E., Degoey R., Henderson K., Kyle R.A., Oken M.M., Bradwell A.R., and Greipp P.R. Appraisal of immunoglobulin free light chain as a marker of response. Blood 111 (2008) 4908-4915
29. Minges Wols H.A., Ippolito J.A., Yu Z., Palmer J.L., White F.A., Le P.T., and Witte P.L. The effects of microenvironment and internal programming on plasma cell survival. Int. Immunol. 19 (2007) 837-846
30. Matsui W., Wang Q., Barber J.P., Brennan S., Smith B.D., Borrello I., McNiece I., Lin L., Ambinder R.F., Peacock C., Watkins D.N., Huff C.A., and Jones R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68 (2008) 190-197
31. Katz B.Z. Side populations-following the footprints of the elusive multiple myeloma stem cells?. Leuk. Lymphoma 49 (2008) 1657-1658
32. Ge Y., Zhan F., Barlogie B., Epstein J., Shaughnessy Jr. J., and Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br. J. Haematol. 133 (2006) 83-92
33. Avecilla S.T., Hattori K., Heissig B., Tejada R., Liao F., Shido K., Jin D.K., Dias S., Zhang F., Hartman T.E., Hackett N.R., Crystal R.G., Witte L., Hicklin D.J., Bohlen P., Eaton D., Lyden D., de Sauvage F., and Rafii S. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. Med. 10 (2004) 64-71
34. Zipori D. The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev. 25 (2006) 459-467
35. Shoham T., Parameswaran R., Shav-Tal Y., Barda-Saad M., and Zipori D. The mesenchymal stroma negatively regulates B cell lymphopoiesis through the expression of activin A. Ann. N. Y. Acad. Sci. 996 (2003) 245-260
36. Zipori D., and Barda-Saad M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J. Leukoc. Biol. 69 (2001) 867-873
37. Cassese G., Arce S., Hauser A.E., Lehnert K., Moewes B., Mostarac M., Muehlinghaus G., Szyska M., Radbruch A., and Manz R.A. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171 (2003) 1684-1690
38. Dalton W., and Anderson K.C. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin. Cancer Res. 12 (2006) 6603-6610
39. Hoang B., Zhu L., Shi Y., Frost P., Yan H., Sharma S., Sharma S., Goodglick L., Dubinett S., and Lichtenstein A. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107 (2006) 4484-4490
40. Ohwada C., Nakaseko C., Koizumi M., Takeuchi M., Ozawa S., Naito M., Tanaka H., Oda K., Cho R., Nishimura M., and Saito Y. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur. J. Haematol. 80 (2008) 245-250
41. Anderson K.C. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 35 (2007) 155-162
42. Richardson P.G., Mitsiades C., Schlossman R., Munshi N., and Anderson K. New drugs for myeloma. Oncologist 12 (2007) 664-689